Marek Dudziński

  • Citations Per Year
Learn More
Here we perform the first genome-wide association study (GWAS) of multiple myeloma (MM) survival. In a meta-analysis of 306 MM patients treated at UCSF and 239 patients treated at the Mayo clinic, we find a significant association between SNPs near the gene FOPNL on chromosome 16p13 and survival (rs72773978; P=6 × 10(-10)). Patients with the minor allele(More)
Compelling biological and epidemiological evidences point to a key role of genetic variants of the TERT and TERC genes in cancer development. We analyzed the genetic variability of these two gene regions using samples of 2,267 multiple myeloma (MM) cases and 2,796 healthy controls. We found that a TERT variant, rs2242652, is associated with reduced MM(More)
BACKGROUND Genetic background plays a role in multiple myeloma susceptibility. Several single-nucleotide polymorphisms (SNP) associated with genetic susceptibility to multiple myeloma were identified in the last years, but only a few of them were validated in independent studies. METHODS With the aim to conclusively validate the strongest associations so(More)
The idiopathic hypereosinophilic syndrome (HES) comprises a heterogenous group of disorders characterized by marked blood eosinophilia with eosinophilia-associated organ damage. Eight patients with a median age at diagnosis of 42 years (range 19-67) received imatinib mesylate (IM) for FIP1L1-PDGFRα-negative HES resistant to previous conventional treatment.(More)
Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple lines of evidence suggest that genetic factors are involved in MM pathogenesis, and several studies have identified single nucleotide(More)
Elżbieta Iskierka-Jażdżewska, Marek Hus, Krzysztof Giannopoulos, Elżbieta Mądro, Jadwiga Hołojda, Magdalena Piotrowska, Jan M. Zaucha, Weronika Piszczek, Agnieszka Szeremet, Małgorzata Wojciechowska, Paweł Steckiewicz, Wanda Knopińska-Posłuszny, Marek Osowiecki, Joanna DrozdSokołowska, Beata Kumiega, Sławomira Kyrcz-Krzemień, Janusz Hałka, Marek Dudziński,(More)
In this Article, members of the UCSF cohort who had been alive for longer than two years were inadvertently included in the data presented in Table 3. USCF/old treatments should have 109 patients with a hazard ratio of 3.35 and a P value of 0.00028 instead of the 124 patients with a hazard ratio of 3.37 and a P value of 0.00026. The USCF/new patients should(More)
  • 1